Allergan gets FDA approval for post-cataract surgery pain treatment Acuvail

Allergan eye surgery drug gets FDA approval

IRVINE, Calif. — Allergan Inc., which makes eye-care products and Botox, said Thursday it received Food and Drug Administration approval for its post-cataract surgery eye solution Acuvail.

The eye solution is aimed at treating pain and inflammation following cataract surgery. Allergan said there are more than 3 million cataract surgeries performed in the U.S. each year.

Acuvail is expected to reach the market in September.

Shares of Allergan rose $1.22, or 2.4 percent, to $51.75 in afternoon trading. The stock has traded between $28.95 and $61.72 over the last 52 weeks.


Leave a Reply

Protected by Comment Guard Pro